Cartesian maps the path for an autoimmune disease cell therapy

Now Cartesian Therapeutics, a private, Maryland-based biotech, reckons it has cracked the problem by using mRNA to generate Car-T cells, a procedure not dependent on cell engraftment and thus not requiring lymphodepletion. Even better, its myasthenia gravis trial, just published in Lancet Neurology, has shown impressive efficacy in most patients.